|This study was ongoing in France when Pharm-Olam was approached to assist in enrollment.
Our initial goal was to enroll 50 patients over a period of 6 weeks using 5 sites in an European country. Pharm-Olam achieved this goal 2 weeks early and the sponsor extended enrollment.
Over a 5 month period Pharm-Olam enrolled 242 patients before the total target was achieved globally. In the end, Pharm-Olam enrolled over 60% of the patients with less time and fewer sites.
The study drug later received marketing authorization.